Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Ashwani Gujral of ashwanigujral.com suggests buyin
Biocon shares touched a record high of Rs 1,049.50
The proposed biosimilar trastuzumab is one of the
Following US president-elect Donald Trump’s expl
Bengaluru-based biopharmaceutical firm Biocon on W